A detailed history of Yorktown Management & Research CO Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Yorktown Management & Research CO Inc holds 2,850 shares of NBIX stock, worth $357,703. This represents 0.35% of its overall portfolio holdings.

Number of Shares
2,850
Holding current value
$357,703
% of portfolio
0.35%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$114.58 - $153.15 $326,553 - $436,477
2,850 New
2,850 $328,000
Q2 2021

Aug 03, 2021

SELL
$89.43 - $102.27 $223,575 - $255,675
-2,500 Closed
0 $0
Q2 2020

Aug 11, 2020

BUY
$85.09 - $130.36 $212,725 - $325,900
2,500 New
2,500 $305,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Yorktown Management & Research CO Inc Portfolio

Follow Yorktown Management & Research CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yorktown Management & Research CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Yorktown Management & Research CO Inc with notifications on news.